» Articles » PMID: 28524109

Unexpected Infection Spikes in a Model of Respiratory Syncytial Virus Vaccination

Overview
Date 2017 May 20
PMID 28524109
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Respiratory Syncytial Virus (RSV) is an acute respiratory infection that infects millions of children and infants worldwide. Recent research has shown promise for the development of a vaccine, with a range of vaccine types now in clinical trials or preclinical development. We extend an existing mathematical model with seasonal transmission to include vaccination. We model vaccination both as a continuous process, applying the vaccine during pregnancy, and as a discrete one, using impulsive differential equations, applying pulse vaccination. We develop conditions for the stability of the disease-free equilibrium and show that this equilibrium can be destabilised under certain extreme conditions, even with 100% coverage using an (unrealistic) vaccine. Using impulsive differential equations and introducing a new quantity, the , we showed that eradication could be acheived with 75% coverage, while 50% coverage resulted in low-level oscillations. A vaccine that targets RSV infection has the potential to significantly reduce the overall prevalence of the disease, but appropriate coverage is critical.

Citing Articles

Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review.

Lang J J Math Biol. 2022; 84(4):26.

PMID: 35218424 PMC: 8882104. DOI: 10.1007/s00285-021-01706-y.


Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.

Mezei A, Cohen J, Renwick M, Atwell J, Portnoy A Epidemics. 2021; 35:100444.

PMID: 33662812 PMC: 8262087. DOI: 10.1016/j.epidem.2021.100444.

References
1.
Kinyanjui T, House T, Kiti M, Cane P, Nokes D, Medley G . Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting. PLoS One. 2015; 10(9):e0138018. PMC: 4577090. DOI: 10.1371/journal.pone.0138018. View

2.
Yamin D, Jones F, DeVincenzo J, Gertler S, Kobiler O, Townsend J . Vaccination strategies against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2016; 113(46):13239-13244. PMC: 5135296. DOI: 10.1073/pnas.1522597113. View

3.
La Via W, Marks M, Stutman H . Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention. J Pediatr. 1992; 121(4):503-10. DOI: 10.1016/s0022-3476(05)81135-7. View

4.
Terletskaia-Ladwig E, Enders G, Schalasta G, Enders M . Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study. BMC Infect Dis. 2005; 5:20. PMC: 1084247. DOI: 10.1186/1471-2334-5-20. View

5.
Haynes L . Progress and challenges in RSV prophylaxis and vaccine development. J Infect Dis. 2013; 208 Suppl 3:S177-83. DOI: 10.1093/infdis/jit512. View